DAFNA Capital Management LLC Purchases Shares of 450,000 InflaRx N.V. $IFRX

Key Points

• DAFNA Capital Management LLC has acquired a $459,000 stake in InflaRx N.V., purchasing 450,000 shares of stock, which represents 0.67% ownership in the company.
• InflaRx's stock has risen by 36.8%, currently trading at $1.60, with a market cap of $107.41 million.
• Analysts have mixed ratings on InflaRx: Raymond James downgraded it from "strong-buy" to "outperform," while Oppenheimer reduced its price target from $6.00 to $3.00.

DAFNA Capital Management LLC bought a new position in InflaRx N.V. (NASDAQ:IFRX - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 450,000 shares of the company's stock, valued at approximately $459,000. DAFNA Capital Management LLC owned approximately 0.67% of InflaRx as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently modified their holdings of IFRX. Northern Trust Corp increased its position in InflaRx by 1,933.1% in the fourth quarter. Northern Trust Corp now owns 666,845 shares of the company's stock worth $1,647,000 after purchasing an additional 634,045 shares during the last quarter. Geode Capital Management LLC increased its position in InflaRx by 32.8% in the fourth quarter. Geode Capital Management LLC now owns 48,136 shares of the company's stock worth $119,000 after purchasing an additional 11,900 shares during the last quarter. Raymond James Financial Inc. bought a new stake in InflaRx in the fourth quarter worth $1,576,000. Cubist Systematic Strategies LLC bought a new stake in InflaRx in the fourth quarter worth $55,000. Finally, XTX Topco Ltd bought a new stake in InflaRx in the first quarter worth $38,000. Hedge funds and other institutional investors own 42.39% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the stock. HC Wainwright assumed coverage on shares of InflaRx in a research report on Tuesday. They issued a "buy" rating and a $6.00 price target on the stock. Oppenheimer reduced their price target on shares of InflaRx from $6.00 to $3.00 and set an "outperform" rating on the stock in a research report on Thursday, May 29th. Finally, Raymond James Financial cut shares of InflaRx from a "strong-buy" rating to an "outperform" rating and set a $2.00 price target on the stock. in a research report on Thursday, May 29th. Five research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, InflaRx presently has a consensus rating of "Buy" and an average price target of $6.20.

InflaRx Trading Down 1.1%

Shares of IFRX traded down $0.02 during trading hours on Wednesday, reaching $1.73. 1,111,056 shares of the company traded hands, compared to its average volume of 449,012. The firm has a market cap of $116.13 million, a price-to-earnings ratio of -2.16 and a beta of 1.43. InflaRx N.V. has a 12-month low of $0.71 and a 12-month high of $2.82. The stock's fifty day moving average price is $0.91 and its 200 day moving average price is $1.14.

InflaRx (NASDAQ:IFRX - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported ($0.24) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.24). The company had revenue of $0.05 million for the quarter, compared to analysts' expectations of $0.02 million. On average, research analysts forecast that InflaRx N.V. will post -1.04 earnings per share for the current year.

About InflaRx

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.